Tana, my recollection when I attended a number of investor presentation held by Avexa was a continual belief that ATC as a 2nd line therapy would have a market share of around 20% and would generate approx $500-600M in annual sales.
Others may be able to confirm. There has also been a few posts stating a 20% royalties deal would generate about $100M in revenue for AVX
- Forums
- ASX - By Stock
- AVX
- looking good
looking good, page-15
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)